Catalog No.
DVV00333
Expression system
E. coli
Species reactivity
SARS-CoV-2 (2019-nCoV)
Isotype
DARpin
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MP0420, D614G variant, B.1.351/Beta, P.1/Gamma, B.1.617.2/Delta, AY.2/Delta Plus, AY.4.2/Delta Plus, Lambda(C.37), Mu (B.1.621), Omicron (B.1.1.529, BA.1), Omicron (B.1.1.529, BA.2)
Clone ID
Ensovibep
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial., PMID:39922466
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study., PMID:38854392
Viral Kinetics Model of SARS-CoV-2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection., PMID:38676291
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study., PMID:37057679
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19., PMID:36802896
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19., PMID:36802894
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study., PMID:36214216
[Current and future therapeutic options for COVID-19]., PMID:36036702
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial., PMID:35939810
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants., PMID:35864170
DARPins score against COVID-19., PMID:35296825
COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference., PMID:34933044
Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs., PMID:34793836
For research use only. Not for human or drug use.
